-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Entolimod in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Entolimod in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Entolimod in Non-Small Cell Lung Cancer Drug Details: Entolimod (CBLB-502)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BT-8009 in Peritoneal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BT-8009 in Peritoneal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BT-8009 in Peritoneal Cancer Drug Details: BT-8009 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Naltrexone Hydrochloride in Crohn’s Disease (Regional Enteritis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Naltrexone Hydrochloride in Crohn's Disease (Regional Enteritis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Naltrexone Hydrochloride in Crohn's Disease (Regional Enteritis) Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Metenkefalin in Human Immunodeficiency Virus (HIV) Infections (AIDS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Metenkefalin in Human Immunodeficiency Virus (HIV) Infections (AIDS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Metenkefalin in Human Immunodeficiency Virus (HIV) Infections (AIDS)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Metenkefalin in Kaposi Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Metenkefalin in Kaposi Sarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Metenkefalin in Kaposi Sarcoma Drug Details: IRT-101 (methionine-enkephalin) is under development for...
-
Product Insights
Addictive Disorders – Drugs In Development, 2023
Global Markets Direct’s, ‘Addictive Disorders - Drugs In Development, 2023’, provides an overview of the Addictive Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Addictive Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Fibromyalgia (Fibromyalgia Syndrome) – Drugs In Development, 2023
Global Markets Direct’s, ‘Fibromyalgia (Fibromyalgia Syndrome) - Drugs In Development, 2023’, provides an overview of the Fibromyalgia (Fibromyalgia Syndrome) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Fibromyalgia (Fibromyalgia Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Kaposi Sarcoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Kaposi Sarcoma - Drugs In Development, 2023’, provides an overview of the Kaposi Sarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Kaposi Sarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Secondary Progressive Multiple Sclerosis (SPMS) – Drugs In Development, 2023
Global Markets Direct’s, ‘Secondary Progressive Multiple Sclerosis (SPMS) - Drugs In Development, 2023’, provides an overview of the Secondary Progressive Multiple Sclerosis (SPMS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Secondary Progressive Multiple Sclerosis (SPMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Poliomyelitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Poliomyelitis - Drugs In Development, 2023’, provides an overview of the Poliomyelitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Poliomyelitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...